RedHill Biopharma Adds Board Members
This article was originally published in Scrip
Executive Summary
Tel-Aviv, Israel-based RedHill Biopharma Ltd. has named Dr. June S. Almenoff and Theresa M. Stevens to its advisory board. Almenoff was recently president, principal executive officer and chief medical officer of Furiex Pharmaceuticals. During her four year tenure, the company's valuation increased approximately 10-fold, culminating in its acquisition by Forest Labs/Actavis plc for approximately $1.2bn in 2014. Stevens was previously chief corporate development officer and senior vice president at Aptalis Pharma (now Actavis plc), leading the company's global M&A, strategy and business development operations.